Actively Recruiting // Clinical Trials // Mark Lucarelli // Oculoplastics // Thyroid Eye Disease // Aug 02 2022

A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects with Active, Moderate to Severe Thyroid Eye Disease (TED)

  • Sponsor: Sling Therapeutics, Inc.
  • Principal Investigator: Mark Lucarelli, MD
  • Study Coordinator: Kris Dietzman

Study Objective:

To study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs. placebo, at 24 weeks in the treatment of subjects with active, moderate to severe thyroid eye disease (TED).

Study Design:

Subjects will be randomized 1:1:1 to receive either 75 mg linsitinib, 150 mg linsitinib or placebo. All subjects will enter a 24-week Double mask Treatment Period, during which study drug will be administered on Day 1 (Baseline), and twice daily through Week 24.

Inclusion Criteria:

  • Clinical diagnosis of Graves’ Disease and/or autoimmune Hashimoto’s thyroiditis associated with active moderate to severe TED with a CAS ≥ 4 (on the 7- item scale) for the most severely affected eye (primary study eye) at Screening and Baseline
  • Confirmed active TED (not sight-threatening but has an appreciable impact on daily life, with onset (as determined by patient records) within 12 months prior to the Baseline visit and usually associated with one or more of the following: lid retraction ≥ 2 mm, moderate or severe soft tissue involvement, exophthalmos ≥ 3 mm above normal for race and gender, and/or inconstant or constant diplopia.
  • Subjects must be euthyroid (defined as normal TSH) or, have subclinical hyperthyroidism (defined as normal FT4 and FT3 with TSH below the normal range).
  • Does not require immediate surgery, radiotherapy or other ophthalmological intervention at the time of Screening and is not planning for any such treatment during the course of the study.


Exclusion Criteria:

  • Decreased best corrected visual acuity due to optic neuropathy as defined by a decrease in vision of 2 lines on the Snellen chart, new visual field defect, or color defect secondary to optic nerve involvement within the last 6 months.
  • Corneal decompensation unresponsive to medical management.
  • Previous orbital irradiation or surgery.
  • Any steroid use (intravenous [IV] or oral) with a cumulative dose equivalent to > 1g of methylprednisolone or equivalent for the treatment of TED within 3 months of Screening.
  • Prior IGF-1R inhibitor therapy for any condition.

Contact Kris Dietzman with questions, (608) 263-9035

For more information about this study, visit clinicaltrials.gov:

visit clinicaltrials.gov